{"id":"shr-a1811-for-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"SHR-A1811 functions as a bispecific monoclonal antibody designed to target dual immune pathways, likely involving PD-1/PD-L1 and CTLA-4 or similar checkpoint axes. By blocking inhibitory signals on T cells through multiple mechanisms simultaneously, the drug aims to overcome tumor immune evasion and generate more potent anti-tumor immunity than single-checkpoint inhibitors alone.","oneSentence":"SHR-A1811 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:53:08.051Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07196774","phase":"PHASE3","title":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-10-23","conditions":"Early-stage or Locally Advanced HER2-positive Breast Cancer","enrollment":740},{"nctId":"NCT07275242","phase":"PHASE1","title":"A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-12-23","conditions":"Solid Tumor","enrollment":107},{"nctId":"NCT07110571","phase":"PHASE2","title":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-28","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":200},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT07111832","phase":"PHASE3","title":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-20","conditions":"PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer","enrollment":400},{"nctId":"NCT07051486","phase":"PHASE2","title":"A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-10-11","conditions":"Recurrent or Metastatic Cervical Cancer","enrollment":60},{"nctId":"NCT06840002","phase":"PHASE1, PHASE2","title":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-03-18","conditions":"Ovarian Cancer","enrollment":150},{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT07102901","phase":"PHASE2","title":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-09-05","conditions":"Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT06859775","phase":"PHASE1, PHASE2","title":"SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-04-25","conditions":"Recurrent or Metastatic Cervical Cancer","enrollment":100},{"nctId":"NCT06990516","phase":"PHASE1, PHASE2","title":"SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Cancer","enrollment":90},{"nctId":"NCT06990503","phase":"PHASE3","title":"SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT06828354","phase":"PHASE3","title":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT05911958","phase":"PHASE2","title":"A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2023-07-05","conditions":"HER2 Low Breast Carcinoma","enrollment":66},{"nctId":"NCT06592625","phase":"PHASE2","title":"Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-09-20","conditions":"Untreated Early-stage or Locally Advanced Breast Cancer","enrollment":60},{"nctId":"NCT04818333","phase":"PHASE1, PHASE2","title":"A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-23","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":157},{"nctId":"NCT05353361","phase":"PHASE2","title":"A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-05-23","conditions":"Breast Cancer","enrollment":402},{"nctId":"NCT05896020","phase":"PHASE2","title":"A Study of SHR-A1811 in Subjects With Gynaecologic Oncology","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-07-10","conditions":"Gynaecological Malignancies","enrollment":225},{"nctId":"NCT05845138","phase":"PHASE1, PHASE2","title":"A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2023-07-25","conditions":"Breast Cancer","enrollment":116},{"nctId":"NCT05814354","phase":"PHASE3","title":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-06-30","conditions":"Breast Cancer","enrollment":530},{"nctId":"NCT05349409","phase":"PHASE2","title":"A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-06-09","conditions":"Advanced Solid Tumors","enrollment":212}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SHR-A1811 group"],"phase":"phase_3","status":"active","brandName":"SHR-A1811 for Injection","genericName":"SHR-A1811 for Injection","companyName":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","companyId":"suzhou-suncadia-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-A1811 for Injection is being studied in a Phase II clinical trial for the treatment of gynaecological malignancies. The exact mechanism of SHR-A1811 is unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}